• Pentixapharm Holding agreed with Eckert & Ziegler to extend its EUR 18.5 million convertible bond maturity to December 31, 2030.
• The annual interest rate rises from 4% to 6% on January 1, 2027.
• Undrawn funding of EUR 13.5 million remains available until June 30, 2030.
• The agreement also permits early redemption at principal plus accrued interest.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pentixapharm Holding AG published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.